Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer.

被引：0
|
作者：
Kapar, Caner
Tugcu, Volkan
Sahin, Selcuk
Guler, Haydar
Kilickap, Saadettin
Tural, Deniz
机构：
[1] Bakirkoy Res & Educ Hosp, Istanbul, Turkiye
[2] Istinye Univ, Dept Urol, Istanbul, Turkiye
[3] Bakirkoy Res & Educ Hosp, Dept Urol, Istanbul, Turkiye
[4] Kanuni Res & Educ Hosp, Dept Urol, Istanbul, Turkiye
[5] Istinye Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye
[6] Univ Hlth Sci, Dept Med Oncol, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
    Naqvi, Syed Arsalan Ahmed
    Bin Riaz, Irbaz
    Imran, Manal
    Bin Zafar, Muhammad Daim
    Faisal, Kunwer Sufyan
    Bin Riaz, Zaryab
    Singh, Parminder
    Bryce, Alan Haruo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
    Chowdhury, S.
    Bjartell, A.
    Agarwal, N.
    Chung, B. H.
    Given, R. W.
    Gomes, A. J. Pereira de Santana
    Merseburger, A. S.
    Ozguroglu, M.
    Soto, A. Juarez
    Uemura, H.
    Ye, D.
    Brookman-May, S. D.
    Londhe, A.
    Bhaumik, A.
    Mundle, S. D.
    Larsen, J. S.
    McCarthy, S. A.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2023, 34 (05) : 477 - 485
  • [3] Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide
    Lowentritt, Benjamin
    Pilon, Dominic
    Khilfeh, Ibrahim
    Rossi, Carmine
    Muser, Erik
    Kinkead, Frederic
    Waters, Dexter
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 253.e1 - 253.e9
  • [4] APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES
    Chowdhury, Simon
    Bjartell, Anders
    Agarwal, Neeraj
    Chung, Byung Ha
    Given, Robert W.
    Pereira de Santana Gomes, Andrea J.
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Juarez Soto, Alvaro
    Uemura, Hirotsugu
    Ye, Dingwei
    Lopez-Gitlitz, Angela
    Londhe, Anil
    Mundle, Suneel
    Larsen, Julie S.
    McCarthy, Sharon
    Chi, Kim N.
    JOURNAL OF UROLOGY, 2020, 203 : E250 - E250
  • [5] Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
    Lowentritt, Benjamin
    Pilon, Dominic
    Khilfeh, Ibrahim
    Rossi, Carmine
    Muser, Erik
    Kinkead, Frederic
    Waters, Dexter
    Ellis, Lorie
    Lefebvre, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [6] Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project)
    Maughan, Benjamin L.
    Liu, Yanfang
    Mundle, Suneel
    Wang, Xiayi
    Karsh, Lawrence Ivan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.
    Sutera, Philip
    Deek, Matthew
    Guler, Ozan Cem
    Hurmuz, Pervin
    Reyhan, Mehmet
    Rowe, Steven P.
    Hrinivich, William
    Ren, Lei
    Kiess, Ana Ponce
    Song, Daniel Y.
    Oymak, Ezgi
    Pienta, Kenneth J.
    Pomper, Martin
    Feng, Felix Y.
    Ozyigit, Gokhan
    Tran, Phuoc T.
    Phillips, Ryan
    Onal, Huseyin Cem
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer
    Fujimoto, Naohiro
    Shiota, Masaki
    Matsukawa, Takuo
    Minato, Akinori
    Tomisaki, Ikko
    Ohnishi, Rei
    Eto, Masatoshi
    IN VIVO, 2021, 35 (02): : 1101 - 1108
  • [9] Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).
    Du, Shawn
    Pilon, Dominic
    Khilfeh, Ibrahim
    Muser, Erik
    Rossi, Carmine
    Kinkead, Frederic
    Diaz, Lilian
    Korsiak, Jill
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 51 - 51
  • [10] Prostate-specific antigen (PSA) measurements' association with metastasis and mortality in patients with nmCRPC (non-metastatic castration resistant prostate cancer).
    Li, Sophia
    Ding, Zhijie
    Lin, Jennifer H.
    Behl, Ajay S.
    Pericone, Chris
    Deshmukh, Siddhant
    Macomson, Brian
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345